Workflow
Perspective Therapeutics(CATX)
icon
Search documents
Perspective Therapeutics(CATX) - 2023 Q4 - Annual Report
2023-08-10 16:00
30 Table of Contents Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐ FORM 10-Q Commission File No. 001-33407 (Exact name of registrant as specified in its charter) 350 Hills St., Suite 106, Richland, Washington 99354 (Address of principal executive offices) (Zip Code) Title of each class Trading Symbol(s)Name of each exchange on which registered Common Stock, $0.001 par value CATX NYSE American Indicate by check mark whether the reg ...
Perspective Therapeutics(CATX) - 2023 Q3 - Quarterly Report
2023-05-14 16:00
Commission File No. 001-33407 Registrant's telephone number, including area code: (509) 375-1202 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. i PERSPECTIVE THERAPEUTICS, INC. Perspective Therapeutics, Inc. and ...
Perspective Therapeutics(CATX) - 2023 Q1 - Quarterly Report
2022-11-13 16:00
Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ___________ ...
Perspective Therapeutics(CATX) - 2023 Q1 - Earnings Call Transcript
2022-11-10 23:55
Isoray, Inc. (ISR) Q1 2023 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Mark Levin - IR Lori Woods - CEO Thijs Spoor - CEO, Viewpoint Molecular Targeting Jonathan Hunt - CFO Conference Call Participants Mike Ott - Oppenheimer Operator Good day, ladies and gentlemen. And welcome to the Isoray, Inc. Q1 FY 2023 Call. At this time, all participants have been placed on a listen-only mode and the floor will be open for questions-and-comments after the presentation. It is now my pleas ...
Perspective Therapeutics(CATX) - 2022 Q4 - Earnings Call Transcript
2022-09-29 02:35
Isoray, Inc. (ISR) Q4 2022 Earnings Conference Call September 28, 2022 4:30 PM ET Company Participants Mark Levin - Investor Relations Lori Woods - Chief Executive Officer Thijs Spoor - Chief Executive Officer, Viewpoint Molecular Targeting Jonathan Hunt - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Mike Ott - Oppenheimer Operator Good afternoon, ladies and gentlemen. And welcome to the Isoray, Inc. Fourth Quarter Fiscal Year 2022 Call. At this time, all partici ...
Perspective Therapeutics(CATX) - 2022 Q4 - Annual Report
2022-09-27 16:00
Table of Contents United States Securities and Exchange Commission WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File No. 001-33407 Isoray, Inc. (Exact name of registrant as specified in its charter) Delaware 41-1458152 (State of incorpo ...
Perspective Therapeutics(CATX) - 2022 Q3 - Quarterly Report
2022-05-12 16:00
Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Co ...
Perspective Therapeutics(CATX) - 2022 Q3 - Earnings Call Transcript
2022-05-11 00:16
Start Time: 16:30 January 1, 0000 5:00 PM ET Isoray, Inc. (ISR) Q3 2022 Earnings Conference Call May 10, 2022, 16:30 PM ET Company Participants Lori Woods - CEO Jonathan Hunt - CFO Mark Levin - IR Conference Call Participants Frank Takkinen - Lake Street Capital Markets Mike Ott - Oppenheimer Tim Chiang - Northland Operator Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to the Isoray's Fiscal 3Q 2022 Earnings Call. At this time, all participants will are in a listen-only mode. Afte ...
Perspective Therapeutics(CATX) - 2022 Q2 - Earnings Call Transcript
2022-02-09 01:45
Isoray, Inc. (ISR) Q2 2022 Earnings Conference Call February 8, 2022 4:30 PM ET Company Participants Mark Levin - IR Lori Woods - CEO Jonathan Hunt - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Mike Ott - Oppenheimer Tim Chiang - Northland Capital Kyle Krueger - Apollo capital Operator Good afternoon, ladies and gentlemen, and welcome to the IsoRay Fiscal Second Quarter 2022 Earnings Call for the quarter ended December 31,2021. At this time, all participants have been place ...
Perspective Therapeutics(CATX) - 2022 Q2 - Quarterly Report
2022-02-08 16:00
Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ ...